Literature DB >> 6693949

Hyponatremia and natriuresis following subarachnoid hemorrhage in a monkey model.

P B Nelson, S Seif, J Gutai, A G Robinson.   

Abstract

A monkey model of subarachnoid hemorrhage (SAH) was used to study both the incidence of hyponatremia and natriuresis and the associated changes in antidiuretic hormone (ADH) secretion and salt and water balance. Following SAH, seven of nine monkeys became natriuretic and hyponatremic. The natriuretic period lasted an average of 4.4 +/- 0.4 days. The mean nadir of serum sodium content was 125.7 +/- 1.6 mEq/liter, and occurred on the average on the 5th day following SAH. The sodium balance after SAH was negative as compared to the preoperative positive sodium balance (p less than 0.001). The plasma vasopressin level was usually elevated for a day following surgery, but there was no significant difference in the levels during the preoperative period and during the period of natriuresis following SAH. The daily urine output and aldosterone levels were not significantly different, and the plasma volume was slightly, but not significantly, decreased after SAH. Four of the animals that had a hyponatremic and natriuretic response following SAH showed a normal regulation of vasopressin in response to both a water challenge and hypertonic saline challenge. The three monkeys that underwent sham procedures did not become hyponatremic and natriuretic postoperatively. The sham-operated monkeys did not show significant differences in their plasma vasopressin levels, urine volume, plasma volume, and aldosterone levels following surgery. These observations are more consistent with primary natriuresis as the cause of hyponatremia rather than the syndrome of inappropriate secretion of ADH. The cause of the renal loss of sodium is not known, but the possibility of a brain natriuretic factor or an alteration in the neural control of the kidney should be considered.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693949     DOI: 10.3171/jns.1984.60.2.0233

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Rapid natriuresis and preventive hypervolaemia for symptomatic vasospasm after subarachnoid haemorrhage.

Authors:  K Okuchi; M Fujioka; A Fujikawa; A Nishimura; T Konobu; S Miyamoto; T Sakaki
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

2.  Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma.

Authors:  M Filippella; P Cappabianca; L M Cavallo; A Faggiano; G Lombardi; Divitiis E de; A Colao
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

3.  Digoxin-like immunoreactive substance in patients with aneurysmal subarachnoid haemorrhage.

Authors:  E F Wijdicks; M Vermeulen; P van Brummelen; N C den Boer; J van Gijn
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

Review 4.  Cerebral salt wasting syndrome distinct from the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).

Authors:  T Yamaki; A Tano-oka; A Takahashi; T Imaizumi; K Suetake; K Hashi
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

5.  Atrial natriuretic peptide-LI following subarachnoid haemorrhage in man.

Authors:  R Juul; L Edvinsson; R Ekman; T A Frederiksen; G Unsgård; S E Gisvold
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

6.  Hyponatremia hypo-osmolarity in neurosurgical patients. "Appropriate secretion of ADH" and "cerebral salt wasting syndrome".

Authors:  F Vingerhoets; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

7.  Hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): therapeutic decision-making in real-life cases.

Authors:  Maurice Laville; Volker Burst; Alessandro Peri; Joseph G Verbalis
Journal:  Clin Kidney J       Date:  2013-11

Review 8.  Natriuretic hormones, endogenous ouabain, and related sodium transport inhibitors.

Authors:  John M Hamlyn
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-03       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.